Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
Department of Urology, Mayo Clinic, Rochester, MN.
Am J Kidney Dis. 2022 Jan;79(1):125-128. doi: 10.1053/j.ajkd.2021.05.016. Epub 2021 Jul 7.
Primary hyperoxaluria (PH) is a group of genetic disorders that result in an increased hepatic production of oxalate. PH type 3 (PH3) is the most recently identified subtype and results from mutations in the mitochondrial 4-hydroxy-2-oxoglutarate aldolase gene (HOGA1). To date, there have been 2 cases of kidney failure reported in PH3 patients. We present a case of a young man with a history of recurrent urinary tract infections and voiding dysfunction who developed kidney failure at 33 years of age. He developed a bladder stone and bilateral staghorn calculi at 12 years of age. Initial metabolic evaluation revealed hyperoxaluria with very low urinary citrate excretion on multiple measurements for which he was placed on oral citrate supplements. Further investigation of the hyperoxaluria was not completed as the patient was lost to follow-up observation until he presented at 29 years of age with chronic kidney disease stage 4 (estimated glomerular filtration rate 24mL/min/1.73m). Hemodialysis 3 times a week was started at 33 years of age, and subsequent genetic testing revealed a homozygous HOGA1 mutation (C.973G>A p.Gly325Ser) diagnostic of PH3. The patient is currently being evaluated for all treatment options including possible liver/kidney transplantation. All cases of a childhood history of recurrent urinary stone disease with marked hyperoxaluria should prompt genetic testing for the 3 known PH types. Hyperhydration and crystallization inhibitors (citrate) are standard of care, but the role of RNA interference agents for all 3 forms of PH is also under active study.
原发性高草酸尿症 (PH) 是一组遗传疾病,导致肝脏草酸产量增加。PH 型 3 (PH3) 是最近发现的亚型,由线粒体 4-羟基-2-氧代戊二酸醛缩酶基因 (HOGA1) 的突变引起。迄今为止,已有 3 例 PH3 患者报告肾衰竭。我们报告了一例年轻男性,有反复发作尿路感染和排尿功能障碍史,33 岁时发生肾衰竭。他 12 岁时出现膀胱结石和双侧鹿角状结石。最初的代谢评估显示高草酸尿症,多次测量尿枸橼酸盐排泄极低,因此他服用了口服枸橼酸盐补充剂。由于患者失访,未完成对高草酸尿症的进一步调查,直到 29 岁时出现慢性肾脏病 4 期(估计肾小球滤过率 24mL/min/1.73m)。33 岁时开始每周进行 3 次血液透析,随后的基因检测显示 HOGA1 突变纯合子(C.973G>A p.Gly325Ser),诊断为 PH3。目前正在对所有治疗方案进行评估,包括可能的肝/肾移植。所有有儿童期反复发作尿路结石病史和明显高草酸尿症的病例均应进行 3 种已知 PH 类型的基因检测。高水化和结晶抑制剂(枸橼酸盐)是标准治疗方法,但所有 3 种 PH 形式的 RNA 干扰剂的作用也在积极研究中。